Literature DB >> 12426012

Opioids prolong nuclear hepatobiliary imaging when given prior to scanning.

David Barlas1, Donald Margouleff, Lisa Vignogna-Barlas, Martin L Lesser.   

Abstract

Opioid-mediated contraction of the distal common bile duct (CBD) may delay tracer passage during nuclear hepatobiliary imaging (NHI), mimicking pathologic obstruction. We sought to determine if opioid administration before NHI delays CBD visualization and prolongs imaging. The records of 198 Emergency Department patients who underwent NHI were reviewed (after excluding those with evidence for pathologic CBD obstruction). Opioids were administered before NHI in 56 cases. Delayed CBD visualization occurred in 28.6% of subjects who had received opioids and in 12.0% of those who had not (p < 0.01). Delayed imaging was performed in 77.8% of those who had received opioids and in 53.5% of those who had not (p < 0.01). The relative risk of delayed CBD visualization was 1.46 [95%CI 0.65-3.28] for meperidine, 4.18 [95%CI 2.00-8.82] for morphine, and 2.38 [95%CI 1.29-4.39] for any opioid. We conclude that opioids given before NHI are associated with delayed CBD visualization and more imaging sessions. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426012     DOI: 10.1016/s0736-4679(02)00523-1

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  2 in total

1.  Analgesic effect of paracetamol combined with low-dose morphine versus morphine alone on patients with biliary colic: a double blind, randomized controlled trial.

Authors:  Mohammad Reza Farnia; Rasoul Babaei; Farzaneh Shirani; Mehdi Momeni; Majid Hajimaghsoudi; Elnaz Vahidi; Morteza Saeedi
Journal:  World J Emerg Med       Date:  2016

2.  Chronic extrahepatic bile duct dilatation: sonographic screening in the patients with opioid addiction.

Authors:  H Farahmand; M PourGholami; M Sheikh Fathollah
Journal:  Korean J Radiol       Date:  2007 May-Jun       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.